NEW YORK (TheStreet) -- Biotech has been hot this year, especially within the merger and acquisitions space. Now TheStreet's Adam Feuerstein and Gregg Greenberg are highlighting some earnings plays in the sector for next week.Feuerstein said many large-cap biotech companies reported last week and the results were great, with earnings beats and guidance raises. Starting things off will be Ariad Pharmaceuticals ( ARIA), which reports on Wednesday. Analysts are looking for $10 million in sales of its leukemia drug, Iclusig, while the whisper number is actually above that, in the low- to mid-teens. What's even more important though, he says, are sales numbers for the drug that management guides for in the ensuing quarters, since prescription growth is thought to be flattening. Dendreon ( DNDN) reports earnings on Thursday. Feuerstein said the debate has been whether the company will even survive at this rate and that second half sales of Provenge will be the biggest factor. If the outlook is high enough, it will likely quiet the talks of the company's going under. NPS Pharmaceuticals ( NPSP) will also report on Thursday. The company specializes in orphan-disease drugs, which have been on fire this year, according to Feuerstein. He said the focus will be on the early launch of a drug that's meant to counter short bowel syndrome and that the patient tally for it at the end of the year will also be important. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
More from Opinion
Cisco Is Priced Attractively Ahead of Its Earnings Report
Despite challenges in the service provider vertical, Cisco continues to showcase strong business fundamentals. With valuations reaching a low point, this could be the time to own shares ahead of a potential post-earnings rebound.
Disney's Earnings: All Is Well in the House of Mouse
Disney's strong fiscal fourth quarter results provide evidence that the company is riding the right trends in high-quality content creation, direct-to-consumer media distribution and strong consumer discretionary spending.
Alphabet's Share Price Weakness Is an Opportunity to Buy
Alphabet shares pulled back after a third quarter earnings miss that did not accurately reflect the strong performance of the underlying business.